Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.39 |
| ▸ | KCNN4 | O15554 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.36 |
| ▸ | HTR2A | P28223 | 2/20 | 0.36 |
| ▸ | HTR2C | P28335 | 2/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 5/20 | 0.34 |
| ▸ | KCNA3 | P22001 | 2/20 | 0.34 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 4/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2406465 | 0.82 | KCNN4 (0.42) | KIF11KCNN4ALDH1A1HTR2AHTR2C | |
| SCHEMBL4955482 | 0.81 | KCNN4 (0.45) | KIF11KCNN4ALDH1A1HTR2AHTR2C | |
| SCHEMBL28773131 | 0.79 | HTR2A (0.40) | KIF11KCNN4ALDH1A1HTR2AHTR2C | |
| SCHEMBL19910510 | 0.78 | ALDH1A1 (0.40) | KIF11KCNN4ALDH1A1HTR2AHTR2C | |
| SCHEMBL28773037 | 0.77 | KIF11 (0.38) | KIF11KCNN4ALDH1A1HTR2AHTR2C | |
| SCHEMBL28773127 | 0.77 | KDM4E (0.42) | KIF11KCNN4ALDH1A1HTR2AHTR2C | |
| SCHEMBL28772995 | 0.76 | KCNN4 (0.44) | KIF11KCNN4ALDH1A1HTR2AHTR2C | |
| SCHEMBL25657469 | 0.76 | KCNH2 (0.40) | KIF11KCNN4HTR2AHTR2COPRK1 | |
| SCHEMBL16538949 | 0.76 | KIF11 (0.40) | KIF11KCNN4HTR2AHTR2COPRK1 | |
| SCHEMBL15761354 | 0.75 | KIF11 (0.39) | KIF11KCNN4HTR2AHTR2COPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3215116-B1 | A HIGH MOLECULAR WEIGHT BIODEGRADABLE GELATIN-DOXORUBICIN CONJUGATE | UNIV OF THE SCIENCES IN PHILADELPHIA (US) | 2020-09-30 | — | — | EP | disclosed |
| US-10265413-B2 | High molecular weight biodegradable gelatin-doxorubicin conjugate | UNIVERSITY OF THE SCIENCES IN PHILADELPHIA (US) | 2019-04-23 | — | — | US | disclosed |
| US-10005816-B2 | Peptides and their use in food and beverage | The Folger Coffee Company (US) | 2018-06-26 | — | — | US | disclosed |
| US-20170354741-A1 | HIGH MOLECULAR WEIGHT BIODEGRADABLE GELATIN-DOXORUBICIN CONJUGATE | UNIVERSITY OF THE SCIENCES IN PHILADELPHIA (US) | 2017-12-14 | — | — | US | disclosed |
| EP-3215116-A1 | A HIGH MOLECULAR WEIGHT BIODEGRADABLE GELATIN-DOXORUBICIN CONJUGATE | University of the Sciences in Philadelphia (US) | 2017-09-13 | — | — | EP | disclosed |
| EP-2205624-B1 | INSULINOTROPIC PEPTIDE SYNTHESIS USING SOLID AND SOLUTION PHASE COMBINATION TECHNIQUES | CORDEN PHARMA COLORADO INC (US) | 2016-09-07 | — | — | EP | disclosed |
| US-20160165916-A1 | NOVEL PEPTIDES AND THEIR USE IN FOOD AND BEVERAGE | The Folger Coffee Company | 2016-06-16 | — | — | US | disclosed |
| WO-2016077083-A1 | A HIGH MOLECULAR WEIGHT BIODEGRADABLE GELATIN-DOXORUBICIN CONJUGATE | UNIVERSITY OF THE SCIENCES IN PHILADELPHIA (US) | 2016-05-19 | — | — | WO | disclosed |
| WO-2016070241-A1 | TRIAZINE COMPOUNDS, COMPOSITIONS AND SYNTHESIS | CTXT PTY LTD (AU) | 2016-05-12 | — | — | WO | disclosed |
| US-20140343227-A1 | Diketopiperazine Forming Dipeptidyl Linker | LONZA AG (CH) | 2014-11-20 | — | — | US | disclosed |
| US-20080004429-A1 | Insulinotropic peptide synthesis using solid and solution phase combination techniques | ROCHE PALO ALTO LLC | 2008-01-03 | — | — | US | disclosed |
| WO-2007147816-A1 | INSULINOTROPIC PEPTIDE SYNTHESIS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-12-27 | — | — | WO | disclosed |
| EP-1856142-A1 | SYNTHESIS OF PEPTIDE T-1249 USING PEPTIDE INTERMEDIATE FRAGMENTS | F. Hoffmann-Roche AG (CH) | 2007-11-21 | — | — | EP | disclosed |
| EP-1833843-A1 | SYNTHESIS OF PEPTIDE T-20 USING PEPTIDE INTERMEDIATE FRAGMENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-09-19 | — | — | EP | disclosed |
| US-20070213504-A1 | Synthesis using peptide intermediate fragments | ROCHE COLORADO CORPORATION | 2007-09-13 | — | — | US | disclosed |
| US-20060276624-A1 | Synthesis using peptide intermediate fragments | ROCHE COLORADO CORPORATION | 2006-12-07 | — | — | US | disclosed |
| US-20060173163-A1 | Synthesis using peptide intermediate fragments | ROCHE COLORADO CORPORATION | 2006-08-03 | — | — | US | disclosed |
| WO-2006069729-A1 | SYNTHESIS OF PEPTIDE T-1249 USING PEPTIDE INTERMEDIATE FRAGMENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-07-06 | — | — | WO | disclosed |
| WO-2006069727-A2 | SYNTHESIS OF PEPTIDE T-20 USING PEPTIDE INTERMEDIATE FRAGMENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-07-06 | — | — | WO | disclosed |
| WO-2006069728-A1 | SYNTHESIS OF PEPTIDE T-20 USING PEPTIDE INTERMEDIATE FRAGMENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170354741-A1 | HIGH MOLECULAR WEIGHT BIODEGRADABLE GELATIN-DOXORUBICIN CONJUGATE | MMP2, DNASE1L3, DNASE1 | KIF11 905/4885KCNN4 4626/4885ALDH1A1 620/4885 |
| US-10265413-B2 | High molecular weight biodegradable gelatin-doxorubicin conjugate | MMP2, DNASE1L3, DNASE1 | KIF11 905/4885KCNN4 4626/4885ALDH1A1 620/4885 |
| US-20080004429-A1 | Insulinotropic peptide synthesis using solid and solution phase combination techniques | IAPP, GLP1R, GIPR | KIF11 2535/4885KCNN4 3754/4885ALDH1A1 4845/4885 |
| US-20140343227-A1 | Diketopiperazine Forming Dipeptidyl Linker | FAP, IAPP, DNPEP | KIF11 3584/4885KCNN4 4354/4885ALDH1A1 3924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.